-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

Benzinga·10/20/2026 12:35:27
Listen to the news
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $110.